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Tumor suppressors with widespread impact on carcinogenesis control broad spectra of oncogenic path-
ways. Protein degradation is an emerging mechanism by which tumor suppressors regulate a diversity of
pathways and is exemplified by the SCFFbw7 ubiquitin ligase. Rapidly accumulating data indicate that
SCFFbw7 regulates a network of crucial oncoproteins. Importantly, the FBXW7 gene, which encodes Fbw7,
is one of the most frequently mutated genes in human cancers. These studies are yielding important new
insights into tumorigenesis and may soon enable therapies targeting the Fbw7 pathway. Here, we focus
on the mechanisms and consequences of Fbw7 deregulation in cancers and discuss possible therapeutic
approaches.Protein degradation by the ubiquitin-proteasome system (UPS)
controls a broad array of cellular processes (Hershko and Cie-
chanover, 1998). Ubiquitin-mediated proteolysis is regulated,
rapid, and irreversible and has important roles in cell division,
growth, and differentiation. Cancers often contain mutations
targeting the UPS that drive tumorigenesis (Nakayama and
Nakayama, 2006). Indeed, the fundamental importance of the
UPS in tumor cell homeostasis is highlighted by the emergence
of pharmacologic UPS inhibitors as promising cancer therapies.
Perhaps the most commonly deregulated UPS protein in
human cancers is the ubiquitin ligase component Fbw7, which
targets a network of substrates for degradation, including
some key human oncoproteins (Crusio et al., 2010; Welcker
and Clurman, 2008). Most of these substrates are master
transcription factors (TFs), allowing Fbw7 to regulate diverse
pathways with oncogenic potential. Recent progress in many
disciplines has illuminated Fbw7’s central role in tumorigenesis.
Large-scale cancer genome studies have shown that Fbw7 is
among the most mutated cancer genes, mouse models have
demonstrated its potent tumor suppressor functions, and new
substrates and mutational mechanisms have been discovered
that may drive Fbw7-associated cancer. These advances have
not only increased our understanding of Fbw7’s roles in tumori-
genesis, but may also soon enable the development of Fbw7-
targeted therapies.
Fbw7 Is a Ubiquitin Ligase Substrate Receptor
Ubiquitin-mediated proteolysis is instigated by the attachment of
K48 polyubiquitin chains to substrates, which provides a signal
for recognition and degradation by the proteasome (Finley,
2009). In most cases, E3 ubiquitin ligases are needed to recog-
nize substrates and facilitate their ubiquitylation. SCFs (Skp1,
Cullin-1, F box protein) are a class of E3s that use Cullin-1 as a
scaffold and F box proteins as substrate receptors and have
important roles in cancer biology (Figure 1A) (Deshaies and
Joazeiro, 2009; Lee and Diehl, 2014; Skaar et al., 2013). F box
proteins are thus adaptors that bring substrates into proximity
with ubiquitylation enzymes.Fbw7 is an evolutionarily conserved F box protein, and
although beyond the scope of this review, studies of its orthologs
(Cdc4,S. cerevisiae; sel-10,C. elegans; Archipelago,Drosophila)
have yielded fundamental insights into SCFFbw7 function. The
human FBXW7 gene resides on chromosome 4q32, a region
commonly deleted in cancers, and produces three mRNAs,
each under their own transcriptional control (Spruck et al.,
2002). The three Fbw7 mRNAs encode three protein isoforms
that differ only by isoform-specific N-terminal exons that specify
subcellular localization: Fbw7a is nucleoplasmic, Fbw7b is
cytoplasmic, and Fbw7g is nucleolar. All isoforms share three
important functional domains: (1) the D domain mediates Fbw7
dimerization, which regulates substrate binding modes and
ubiquitylation, (2) the F box binds Skp1 and links Fbw7 to the
SCF complex, and (3) the WD40 domain forms a b propeller
that binds phosphorylated substrates (Figure 1B) (Hao et al.,
2007; Orlicky et al., 2003; Tang et al., 2007; Welcker and
Clurman, 2007; Welcker et al., 2013; Zhang and Koepp, 2006).
Fbw7a is thought to perform most Fbw7 functions, although
specific roles for the other isoforms have also been described
(Bonetti et al., 2008; Ekholm-Reed et al., 2013; Grim et al.,
2008; Matsumoto et al., 2011; van Drogen et al., 2006; Welcker
et al., 2004a).
Substrate Phosphorylation Stimulates Fbw7 Binding
Substrate phosphorylation instigates Fbw7 binding to a con-
served Cdc4 phosphodegron (CPD) motif (Koepp et al., 2001;
Nash et al., 2001; Strohmaier et al., 2001; Welcker et al., 2003).
Mutational and structural studies have provided insights into
the interactions between CPDs and Fbw7’s b propeller (Hao
et al., 2007; Orlicky et al., 2003; Tang et al., 2007). CPDs contain
multiple residues that contact Fbw7 and typically include
phosphorylated threonine or serine residues in the ‘‘0’’ and
‘‘+4’’ positions that interact with Fbw7 phosphate-binding
pockets (Welcker and Clurman, 2008). CPD affinity varies among
substrates; high-affinity CPDs contain two phosphorylations and
other optimal residues, whereas low-affinity substrates may
contain a negatively charged amino acid in lieu of a secondCancer Cell 26, October 13, 2014 ª2014 Elsevier Inc. 455
Figure 1. Dimeric SCFFbw7 Regulates a Broad Network of Substrates
(A) Fbw7 binds to both phosphorylated substrates and the rest of the SCF
complex (comprised of Skp1, Cullin-1, Rbx1, and an E2 enzyme), resulting in
substrate polyubiquitylation and degradation by the proteasome. The network
of Fbw7 substrates contains proteins with clear roles in carcinogenesis (shown
in green) and others with emerging roles in Fbw7-associated tumors (shown in
blue; see the main text). Optimal (high-affinity) substrates have recognition
signals termed CPDs that contain two phosphorylated residues (orange ‘‘P’’);
other, lower-affinity CPDs contain a negatively charged amino acid (yellow
‘‘E’’) in place of the second phosphate.
(B) Fbw7 exists as three protein isoforms (a, b, and g) that differ only by their
N-terminal exons. All isoforms share three functional domains that are critical
to their function as ubiquitin ligases: (1) the dimerization domain (‘‘DD’’)
mediates Fbw7 dimerization, (2) the F box binds to the rest of the SCF complex
via Skp1 (see A), and (3) theWD40 domain binds to phosphorylated substrates
and includes the three arginine residues that are mutational hot spots in
cancers.
Figure 2. Possible Mechanisms of Fbw7ARG Missense Mutations in
Cancers
(A) Normal interactions of Fbw7 dimers with monomeric (left) or dimeric (right)
substrates. Each protomer within an Fbw7 dimer can interact with a separate
substrate CPD, leading to greatly increased binding affinity between sub-
strates and Fbw7. The two substrate CPDs can be present within amonomeric
substrate (e.g., cyclin E; left) or separated onto two interacting proteins (e.g.,
SREBP; right). The reduced number of contacts made by suboptimal degrons
is indicated by a dashed line.
(B) Model of heterozygous Fbw7ARG dominant-negative activity in cancers
resulting from the formation of impaired Fbw7WT-Fbw7ARG heterodimers. We
speculate that Fbw7WT-Fbw7ARG heterodimers differentially affect substrates,
depending on CPD affinity. The degradation of high-affinity substrates may still
be driven by the normal protomer of an Fbw7WT-Fbw7ARG heterodimer (left),
whereas suboptimal substrates (depicted by glutamate instead of a second
CPD phosphate) rely on the concerted biding of two CPDs to an Fbw7 dimer
and will not be ubiquitylated by Fbw7WT-Fbw7ARG heterodimers (right).
(C) Fbw7 truncation mutants may also generate heterodimers with Fbw7WT but
are not nearly as frequent in tumors as Fbw7ARG.We therefore speculate that a
full-length Fbw7 protein is critical for the dominant-negative effect of Fbw7ARG,
perhaps by retaining sufficient residual binding affinity (depicted by dashed
line) for substrates with intermediate affinity.
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2007; Nash et al., 2001; Welcker et al., 2013). Importantly, three
arginine residues in Fbw7’s WD40 domain interact with CPD
phosphates and are mutational hot spots in cancers (see below).
Ultimately, the signaling pathways that mediate CPD phos-
phorylation regulate substrate degradation. The presence of
two phosphorylation sites in most CPDs provides a mechanism
through which multiple signals can control substrate degrada-
tion. Most substrates have multiple turnover pathways; there-
fore, the regulation of CPD phosphorylation determines the
context of their degradation by SCFFbw7. Glycogen synthase
kinase 3 (GSK3) phosphorylates the central position of many
CPDs, and this is opposed by mitogen stimulation of the PI3K-
AKT pathway, which inactivates GSK3 (Crusio et al., 2010;
Welcker and Clurman, 2008). It is likely that by coupling Fbw7-
mediated degradation with GSK3 activity, mitogenic signaling
can coordinately stabilize substrates with key roles in cell prolif-
eration (e.g., Myc, cyclin E, and Jun). The abnormal AKT and
PTEN activity commonly found in cancers might similarly allow
oncogenic Fbw7 substrates to accumulate.
Fbw7 dimerization provides another important level of regu-
lation. Because each protomer of an Fbw7 dimer contains a
substrate-binding domain, dimers can simultaneously bind two456 Cancer Cell 26, October 13, 2014 ª2014 Elsevier Inc.CPDs, which is particularly important for substrates with de-
grons that are too weak to drive Fbw7 binding alone (Figures 1
and 2) (Welcker et al., 2013). The combinatorial impact of multi-
ple CPDs allows highly specific control of substrate ubiquityla-
tion. Additionally, dimerization promotes substrate degradation
by expanding the number of substrate lysine residues that are
accessible for ubiquitin conjugation (Hao et al., 2007; Tang
et al., 2007; Welcker et al., 2013).
Oncogenic Fbw7 Substrates: The Drivers of
Fbw7-Associated Cancers
SCFFbw7 targets approximately two dozen proteins with key
roles in proliferation, differentiation, apoptosis, and metabolism
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E andMCL1), Fbw7 substrates are transcriptional regulators that
control complex gene-expression programs; this extends
Fbw7’s impact far beyond its direct substrates. Below, we high-
light only those substrates that are known oncoproteins or have
emerging roles in tumorigenesis.
Critical Oncogenic Fbw7 Substrates
Four Fbw7 substrates stand apart by virtue of their frequent
mutation in many human cancers. c-Myc (hereafter called Myc)
sustains gain-of-function mutations, including amplifications in
solid tumors and translocations in hematologic malignancies.
Myc deregulation promotes tumorigenesis largely through its
transcriptional regulation of proliferation, protein synthesis,
apoptosis, metabolism, and differentiation. Fbw7a mediates
Myc ubiquitylation in the nucleoplasm, whereas Fbw7g ubiquity-
lates Myc in the nucleolus, which inhibits Myc’s ability to pro-
mote cell growth (Bonetti et al., 2008; Grim et al., 2008; Welcker
et al., 2004a, 2004b; Yada et al., 2004). Early work found that
phosphorylation of the threonine 58 (T58) CPD stimulates
Myc degradation (Gregory et al., 2003; Sears et al., 2000), and
this is now known to be mediated by Fbw7. The T58 region is
targeted by missense mutations in lymphomas, suggesting a
crucial role for impaired Myc degradation by Fbw7 (Bahram
et al., 2000; Bhatia et al., 1993). This has been confirmed in
mouse models (see below). N-Myc also contains the T58 CPD
and is commonly amplified in cancers (e.g., neuroblastoma),
but the significance of its degradation by Fbw7 is less well
understood.
Notch proteins are transcriptional regulators of cell fate and
differentiation that are broadly implicated in human cancers;
they are typically dominant oncogenes, although they can be
tumor suppressive in some cancers. All four Notch paralogs
contain motifs homologous with the Notch1 CPD, but most
studies have focused on Notch1 (Fryer et al., 2004; Gupta-Rossi
et al., 2001; O’Neil et al., 2007; Oberg et al., 2001; Thompson
et al., 2007; Wu et al., 2001). Notch1 is processed by a series
of proteolytic cleavages, and the transcriptionally active Notch1
intracellular domain (NICD) is ubiquitylated by SCFFbw7. Acti-
vating Notch1 mutations occur in approximately 50% of T cell
acute lymphoblastic lymphomas (T-ALLs) and often target the
PEST domain, which contains the Fbw7 CPD (Weng et al.,
2004). Fbw7mutations are also common in T-ALL and are mutu-
ally exclusive with Notch PEST mutations, underscoring the
importance of Fbw7-dependent Notch degradation in this dis-
ease (Malyukova et al., 2007; Maser et al., 2007; O’Neil et al.,
2007; Thompson et al., 2007). Furthermore, Fbw7 mutations in
T-ALL may confer resistance to Notch inhibition by g-secretase
inhibitors, which prevent Notch processing (O’Neil et al., 2007).
Cyclin E, in conjunction with its catalytic partner cyclin-depen-
dent kinase 2 (CDK2), regulates cell-cycle entry and progression.
Cyclin E has long been implicated in carcinogenesis, and The
Cancer Genome Atlas (TCGA) studies demonstrating frequent
cyclin E amplifications in solid tumors (e.g., ovarian and breast)
confirm its role as an oncogenic driver. Multisite phosphorylation
of two well-defined CPDs regulates cyclin E stability and period-
icity (Clurman et al., 1996; Grim et al., 2008; Koepp et al., 2001;
Minella et al., 2008; Spruck et al., 2002; Strohmaier et al., 2001;
Welcker et al., 2003; Won and Reed, 1996). Genome instability
is a critical consequence of constitutive cyclin E-CDK2 activityduring the cell cycle caused by its impaired degradation
(Ekholm-Reed et al., 2004; Keck et al., 2007; Loeb et al., 2005;
Minella et al., 2002, 2007; Rajagopalan et al., 2004; Spruck
et al., 1999). This appears to be a central mechanism through
which cyclin E drives carcinogenesis and is opposed by p53
activation.
c-Jun (hereafter called Jun) is a component of the AP-1 TF and
has essential roles in mitogen-stimulated cell proliferation. Jun
overexpression is common in cancers and is thought to drive
oncogenesis; this is supported by the finding of Jun amplifi-
cations in some human cancers, such as liposarcomas. Two
different Jun CPDs have been described, one of which is
mutated in the v-Jun retroviral oncogene (Nateri et al., 2004;
Wei et al., 2005).
Other Oncogenic Fbw7 Substrates
Many Fbw7 substrates have emerging roles in tumorigenesis,
but uncertain contributions to Fbw7-associated cancers.
Myeloid Cell Leukemia 1 (MCL1) is an antiapoptotic protein
that is overexpressed in cancers, and its stabilization in tumors
with Fbw7 mutations causes resistance to chemotherapy (Inu-
zuka et al., 2011; Wertz et al., 2011). MED13/13L is the com-
ponent of the Mediator transcriptional coactivator complex
that recruits CDK8, an oncogene amplified in colorectal cancer
(Davis et al., 2013). Because Mediator is required for all tran-
scription and CDK8 regulates specific oncogenic transcriptional
programs, MED13 degradation may greatly expand Fbw7’s
role in global transcriptional control. PPARg Coactivator-1a
(PGC-1a) is a transcriptional coactivator that coordinates
mitochondrial biogenesis and cellular energetics and has an
expanding role in tumorigenesis (Olson et al., 2008). Similar to
Notch, Kruppel-Like Factor 5 (KLF5) and CCAAT/Enhancer
Binding Protein Delta (C/EBPd) have either oncogenic or tu-
mor-suppressive functions in different cancers (Balamurugan
et al., 2013; Liu et al., 2010; Zhao et al., 2010). TGIF1 is a tran-
scriptional repressor that inhibits transforming growth factor b
signaling, a crucial oncogenic pathway (Bengoechea-Alonso
and Ericsson, 2010a). Additional oncoproteins have been re-
ported to be Fbw7 substrates, but either they lack consensus
CPDs or the contexts of their regulation by Fbw7 requires further
confirmation (e.g., Hif1a, mTOR, Aurora kinase A, and Myb)
(Wang et al., 2012).
Fbw7 Mutations in Human Cancers
Because many of Fbw7’s first reported substrates were potent
oncoproteins, its role as a tumor suppressor was quickly evalu-
ated and confirmed. Early studies showed that 6%–10% of
colorectal carcinomas contain Fbw7mutations, and subsequent
work revealed Fbw7 mutations in a wide range of organ sites,
including a high prevalence in T-ALL and cholangiocarcinoma
(Akhoondi et al., 2007; Welcker and Clurman, 2008). These
studies revealed a high frequency of heterozygous missense
mutations of the three Fbw7 arginine residues that bind CPD
phosphates (R465, R479, and R505), hereafter called Fbw7ARG.
Because these residues make the most critical contacts with
the CPD phosphates and are absolutely required for high-affinity
Fbw7-substrate interactions (Hao et al., 2007; Orlicky et al.,
2003; Tang et al., 2007), Fbw7ARG mutations have a uniquely
profound impact on substrate-binding affinity compared with
other missense mutations. Moreover, Fbw7 dimers, which haveCancer Cell 26, October 13, 2014 ª2014 Elsevier Inc. 457
Table 1. Fbw7 Mutational Frequency in T-ALL Cell Lines and
Patient Samples
Study
Reference
No.
Samples
Source of
Sample
Fbw7 Point
Mutations (%)
Arginine Hot
Spot Mutations/
Total Point
Mutations (%)
O’Neil
et al., 2007
20 cell lines 35 86
81 primary
samples
9 100
Maser
et al., 2007
23 cell lines 43 90
38 primary
samples
29 73
Thompson
et al., 2007
89 primary
samples
17 100
Malyukova
et al., 2007
15 cell lines 33 100
26 primary
samples
31 88
TCGA studies for T-ALL have not been performed; therefore, these data
were collected from the four indicated studies.
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that disable monomers. Fbw7 dimerization thus greatly restricts
the repertoire of deleterious Fbw7 missense mutations to
only these most stringent positions (Welcker et al., 2013). There
are many possible mutations that could produce either Fbw7
null alleles or truncated proteins, but they occur much less
commonly than Fbw7ARG mutations. The strong biologic selec-
tion of Fbw7ARG mutations suggests that they are not simple
loss-of-function alleles and is most consistent with dominant-
negative alleles, which has been confirmed in mouse models
(see below).
TCGA studies have provided a wealth of mutational and
expression data for different cancers (Cancer Genome Atlas
Network, 2012; Kandoth et al., 2013a, 2013b). Although large-
scale studies of T-ALL are still in progress, previous work
indicates that T-ALL represents a special example of Fbw7-
associated cancer withmutations in up to 30%of cases (Table 1)
(Malyukova et al., 2007; Maser et al., 2007; O’Neil et al., 2007;
Thompson et al., 2007). Fbw7 is significantly mutated (>10% of
samples) in at least five tumor types: T-ALL, colorectal adeno-
carcinoma, uterine carcinosarcoma, uterine endometrial carci-
noma, and bladder carcinoma. Other cancers with somewhat
less frequent Fbw7 mutations include stomach adenocarci-
noma, lung squamous cell carcinoma, cervical squamous cell
carcinoma, and head and neck squamous cell carcinoma (Table
2). In contrast, Fbw7 mutations are not found in some cancers,
such as acute myeloid leukemia (AML) and multiple myeloma.
One possibility is that Fbw7 substrate stabilization is detrimental
in these neoplasms. For example, the Fbw7 substrate C/EBPa
suppresses AML (Bengoechea-Alonso and Ericsson, 2010b),
and multiple myelomas require constitutive NF-kB signaling;
therefore, disruption of Fbw7-mediated NF-kB2 ubiquitylation
in these tumors results in cell death (Busino et al., 2012). Despite
extensive studies, the prognostic significance of Fbw7mutations
in cancer remains uncertain. For example, whereas TCGA Pan-
Cancer analyses found Fbw7mutations to be detrimental across
multiple tissue types (Kandoth et al., 2013b), the colorectal-458 Cancer Cell 26, October 13, 2014 ª2014 Elsevier Inc.specific TCGA study found no overlap between Fbw7 mutations
and distant metastases, suggesting that mutations could be
beneficial (Cancer Genome Atlas Network, 2012). Analogous
studies of Fbw7 mutations in T-ALL have similarly yielded
conflicting results.
We performed a meta-analysis of TCGA data using the
cBioPortal for Cancer Genomics online interface to compare
and contrast Fbw7 mutations across cancer types (Table 2)
(Cerami et al., 2012; Gao et al., 2013). These results are based
upon data generated in whole by the TCGA Research Network
(http://cancergenome.nih.gov/) and confirm the striking skewing
toward Fbw7ARG mutations, particularly in organ sites where
Fbw7 is most frequently mutated. Importantly, most tumors
with Fbw7ARG mutations retain a normal second Fbw7 allele.
This notably contrasts with the ‘‘two-hit’’ mutation pattern of
some tumor suppressors. However, nonsense mutations (some-
times in combination with allelic loss) and homozygous null
mutations are found in some tumors; thus, Fbw7 exhibits
classic tumor-suppressor features in these cases. The frequency
and types of Fbw7 mutations vary among organ sites. For
example, colorectal cancers contain the entire spectrum of
Fbw7 mutations (deletions and missense and nonsense muta-
tions), whereas others, such as T-ALLs, exhibit nearly 100%
heterozygous Fbw7ARG mutations (Tables 1 and 2). This sug-
gests that distinct Fbw7 mutations produce unique biologic
outcomes, presumably through differential effects on specific
substrates (see below).
Instead of mutations in Fbw7 itself, some cancers contain sub-
strate CPD mutations that prevent their ubiquitylation, including
Myc CPD mutations in Burkitt’s lymphoma, Notch PEST muta-
tions in T-ALL, and a KLF5 CPD mutation in colon cancer
(Bahram et al., 2000; Bhatia et al., 1993; Bialkowska et al.,
2014; Weng et al., 2004). This suggests particularly important
roles for these substrates in specific tumors. However, the
paucity of single-substrate CPD mutations compared with
Fbw7 mutations suggests that in most cases, Fbw7-associated
tumorigenesis requires the concurrent deregulation of multiple
oncoproteins.
Additional Mechanisms of Fbw7 Disruption in Cancer
Mechanisms other than mutations and allelic loss also impair
Fbw7 function in cancers. Fbw7 is targeted by oncogenic micro-
RNAs such as miR-27, miR-92, and miR-223 in numerous
cancers (Olive et al., 2013; Wang et al., 2014). Promoter hyper-
methylation downregulates Fbw7b expression in breast cancers
and thymomas (Akhoondi et al., 2010; Gu et al., 2008b), and
Fbw7 mRNA is also repressed in melanomas and gliomas,
although the underlying mechanisms are not known (Cheng
et al., 2013; Gu et al., 2008a). Fbw7b is a p53 target gene; there-
fore, p53 mutations may reduce Fbw7 expression (Kimura et al.,
2003). Two Fbw7 substrates feed back to control Fbw7 mRNA
expression: C/EBPd, which may contribute to mammary tumor
metastasis (Balamurugan et al., 2013), and Hes5 (a Notch target
gene) (Sancho et al., 2013). Many studies have examined low
Fbw7 mRNA expression in tumors as a biomarker, which gener-
ally appears to be a high-risk feature.
Fbw7 protein stability is another regulatory mechanism that
has been examined in tumors. One example is Fbw7b degrada-
tion by Parkin, which subsequently inhibits MCL-1 degradation
Table 2. Fbw7 Mutation and Homozygous Deletion Frequency in Selected Cancers
Tumor Type
No.
Samples
Arginine
Hot Spot
Mutations (%)
Nonsense
Mutations (%)
Other Missense
Mutations (%)
All Point
Mutations (%)
Arginine Hot Spot
Mutations/Total
Point Mutations (%)
Homozygous
Deletions (%)
Uterine carcinosarcoma 56 23 4 14 39 59 0
Colon and rectal
adenocarcinoma
212 8 3 6 17 49 0
Uterine corpus
endometrial carcinoma
240 6 3 8 16 37 0
Stomach adenocarcinoma 219 5 2 2 9 59 <1
Urothelial bladder carcinoma 127 3 5 4 9 33 2
Lung squamous cell carcinoma 178 2 2 2 6 36 <1
Head and neck squamous
cell carcinoma
302 2 <1 3 5 33 1
Cutaneous melanoma 262 <1 1 3 4 9 <1
Breast cancer 962 <1 <1 1 2 20 <1
Cervical squamous
adenocarcinoma
36 0 3 3 6 0 0
Lung adenocarcinoma 230 0 1 <1 2 0 0
Glioblastoma multiforme 281 0 <1 0 <1 0 <1
Mutation and copy-number alteration data were derived from analyses of TCGA data using cBioPortal (Cerami et al., 2012; Gao et al., 2013).
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overexpression in cancers destabilizes Fbw7 by directly gener-
ating Fbw7 monomers that are targeted for degradation through
enhanced autoubiquitylation (Min et al., 2012). However, two
other studies have disputed these findings (Kanatsu-Shinohara
et al., 2014; Welcker et al., 2013).
Lessons Learned from Murine Models of Fbw7-
Associated Cancer Models
Germline Fbw7 deletion in mice causes embryonic lethality
(Tetzlaff et al., 2004; Tsunematsu et al., 2004). Therefore, condi-
tional strains have been used to study Fbw7 in normal tissues
and during tumorigenesis. Mice with knockin mutations that
ablate the cyclin E degrons (hereafter termed cyclin EDCPD)
have also been used to specifically study impaired cyclin E
degradation. These models have convincingly demonstrated
that (1) FBXW7 is a bona fide tumor suppressor gene, (2)
Fbw7ARG mutations have unique functional consequences, (3)
specific Fbw7 substrates contribute to tumorigenesis, and (4)
multiple oncogenic pathways cooperate with Fbw7 mutations.
Fbw7 Regulates Stem Cells, Differentiation,
and Genome Stability
Studies of normal tissues have provided valuable insights into
pathways that are also important for tumorigenesis. Fbw7 loss
profoundly affects differentiation and proliferation in stem and
progenitor cell types, often through similar mechanisms. For
example, in neural stem cells and intestinal crypt progenitor
cells, loss of Fbw7 leads to increased proliferation and differen-
tiation defects through the combined actions of Jun and Notch,
respectively (Grim et al., 2012; Hoeck et al., 2010; Sancho et al.,
2010). Similarly, aberrant Notch activity causes differentiation
defects in hepatocytes (Onoyama et al., 2011). Novel TF sub-
strates may mediate differentiation phenotypes in other tissues.
For example, Fbw7 loss reprograms pancreatic ductal cellstoward endocrine lineages by stabilizing Ngn3 (Sancho et al.,
2014).
Fbw7 also controls hematopoietic stem cell (HSC) quiescence
and self-renewal (Matsuoka et al., 2008; Thompson et al., 2008).
HSCs are quickly exhausted after Fbw7 deletion, largely
because of the detrimental effects of Myc overexpression on
proliferation and apoptosis, although impaired cyclin E degrada-
tion also causes defective HSC self-renewal after hematologic
stress (Reavie et al., 2010; Siu et al., 2014). Importantly,
Fbw7ARG/+ HSCs have intermediate Myc abundance compared
with Fbw7/ and Fbw7+/+ HSCs, and they do not exhibit
these phenotypes—suggesting a unique role for heterozygous
Fbw7ARG alleles and dose-dependent Myc effects in preserving
HSC function (King et al., 2013).
These phenotypes have also been studied in cyclin EDCPD
mice to isolate cyclin E from other substrates affected by
Fbw7mutations. Impaired cyclin E degradation causes epithelial
cell hyperproliferation, abnormal cell-cycle control, impaired
erythroid differentiation, and genome instability (Loeb et al.,
2005; Minella et al., 2008).
Colorectal Cancer
Although Fbw7 mutations are found in early stage human colon
adenomas (Rajagopalan et al., 2004), its deletion from the
mouse gut is not sufficient to cause neoplasia. However, loss of
Fbw7 inmice collaborates with other mutations commonly found
in human colorectal cancer (CRC), including APCMin alleles
(which mimic the WNT pathway activation seen in nearly all
human CRC) and p53 loss. When combined with APCMin, both
Fbw7/ and Fbw7ARG/+ mutations decreased tumor latency
and increased tumor burden (Babaei-Jadidi et al., 2011; Davis
et al., 2014; Sancho et al., 2010). However, these neoplasms
did not progress beyond the adenoma stage and were neither
invasive nor metastatic. Fbw7ARG/+ mice exhibited increased
tumorigenesis compared with Fbw7+/ animals, confirming thatCancer Cell 26, October 13, 2014 ª2014 Elsevier Inc. 459
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KLF5 were elevated in Fbw7ARG/+, but not Fbw7+/, tumors (Da-
vis et al., 2014); thus, these proteins may similarly contribute to
Fbw7-associated human CRC and could represent examples
of substrate-specific consequences of Fbw7ARG/+ mutations.
In Fbw7/ tumors, Jun and Notch abundance was increased,
and concurrent Jun deletion decreased tumor size (Sancho
et al., 2010).
In a second approach, p53 and Fbw7 were codeleted from
the mouse gut, which caused advanced adenocarcinomas that
were highly invasive and metastatic (Grim et al., 2012). In accor-
dance with the findings that p53 suppresses cyclin-E-induced
genomic instability caused by Fbw7 loss, these adenocarci-
nomas exhibited a chromosomal instability (CIN) phenotype,
which is the most common form of genome instability in human
CRC but is rare in mouse tumors.
Hematologic Cancers
Unlike CRC, Fbw7 deletion in either T cells or HSCs is sufficient
to cause T-ALL, and this is accelerated by concurrent p53 loss,
PTEN loss, or Notch activation (King et al., 2013; Kwon et al.,
2012; Matsuoka et al., 2008; Onoyama et al., 2007; Thompson
et al., 2008). The specific roles of Fbw7ARG alleles in leukemo-
genesis and leukemia-initiating cells (LICs), rare cells with
stem-cell-like properties (e.g., self-renewal and quiescence)
and important roles in disease propagation and resistance to
therapy, have also been studied (King et al., 2013). Fbw7ARG/+
mice did not develop spontaneous T-ALL, demonstrating
another example of the differences between Fbw7 missense
and homozygous null mutations. However, the Fbw7ARG/+ muta-
tion strongly cooperated with Notch deregulation to drive T-ALL
and resulted in LIC expansion that is largely attributable to
increased Myc abundance. Genetic or pharmacologic Myc inhi-
bition depleted LICs in this model, demonstrating an essential
role for Myc, although this occurs independently of Fbw7 muta-
tional status.
These data suggest that Myc abundance in Fbw7ARG/+ cells is
finely tuned such that it does not affect HSC maintenance while
still being sufficiently elevated to achieve tumorigenic effects in
LICs. This may, in part, explain the high prevalence of Fbw7ARG
mutations in T-ALL. While Myc and Notch are clearly key
players in Fbw7-associated T-ALL, cyclin EDCPD mice also
developed T cell malignancies that exhibited CIN (Siu et al.,
2014), which is not seen in Fbw7ARG/+ T-ALL. Different lesions
in the Fbw7 pathway may thus lead to T-ALL through different
mechanisms. In addition to Fbw7-associated malignancies,
mouse models have also shown that Fbw7 depletion induced
apoptosis of chronic myeloid leukemia (CML) LICs and B cell
lymphomas (Olive et al., 2013; Reavie et al., 2013; Takeishi
et al., 2013).
Consequences of Fbw7ARG Mutations in Cancers
Fbw7’s mutational spectrum strongly suggests that Fbw7ARG
alleles have dominant-negative activity. The mouse models
described above confirm this idea and demonstrate that hetero-
zygous Fbw7ARG mutations impact Fbw7 function intermediate
to that caused by single allele loss and homozygous null muta-
tions. The concept that this intermediate Fbw7 inactivation
favors tumorigenesis has been termed the ‘‘just-enough’’ hy-
pothesis (Davis and Tomlinson, 2012), and the stabilization of
Myc in Fbw7ARG/+ HSCs to levels that favor leukemogenesis,460 Cancer Cell 26, October 13, 2014 ª2014 Elsevier Inc.but not apoptosis, most likely represents this mechanism (King
et al., 2013).
Two important aspects of Fbw7ARG mutations remain poorly
understood: (1) how do they produce dominant-negative effects,
and (2) why are they so frequently selected for in tumors
compared with nonsense and homozygous null mutations? To
understand these issues, we believe it is crucial to consider
Fbw7’s mode of action as a dimer, which enhances substrate-
binding affinity by engaging multiple CPDs simultaneously
(Figure 2A) (Welcker et al., 2013). Because Fbw7ARG can
dimerize with wild-type Fbw7 and potentially produce impaired
Fbw7WT-Fbw7ARG heterodimers (that contain only a single intact
WD40 domain), we suggest that Fbw7ARG proteins dominantly
inhibit wild-type Fbw7 (Figure 2B).
Fbw7WT-Fbw7ARG heterodimers may also have special prop-
erties that produce substrate-specific effects (Welcker and
Clurman, 2008). While the ubiquitylation of low-affinity sub-
strates depends upon both substrate-binding domains of an
Fbw7WT-Fbw7WT dimer, other substrates may have enough
binding affinity to be ubiquitylated by Fbw7WT-Fbw7ARG hetero-
dimers that contain only a single substrate-binding domain
(Figure 2B). Therefore, dimer-dependent substrate interactions
might account for the selection of heterozygous Fbw7ARG muta-
tions in cancers by allowing Fbw7WT-Fbw7ARG heterodimers to
target substrates whose degradation is permissive or advanta-
geous for tumorigenesis, while sparing the oncoproteins that
drive tumor formation. Finally, although truncated Fbw7 proteins
that can dimerize with Fbw7WT might similarly act as dominant
negatives, these types of mutations are less common. We sug-
gest that the selection for mutations that produce full-length
Fbw7ARG protein reflects important, yet undefined, roles for
continued interactions between substrates and a mutated, but
full-length, Fbw7 protein (Figure 2C).
Therapeutic Strategies Targeting the Fbw7 Pathway in
Cancer
Given the high prevalence of Fbw7 mutations, the development
of therapies targeting the Fbw7 pathway may have great poten-
tial. Figure 3 shows four possible therapeutic approaches; the
first three specifically target tumors with Fbw7 mutations,
whereas the fourth may represent a more general treatment
strategy.
First, because Fbw7ARG proteins have decreased affinity
for substrates, small-molecule agonists might increase the
Fbw7ARG-substrate binding affinity to levels that would restore
substrate ubiquitylation (Figure 3A). These agonists could act
at the substrate-Fbw7 interface, similar to the plant hormone
Auxin that functions as a ‘‘molecular glue’’ between an F box
protein and its substrate (Tan et al., 2007). Alternatively,
Fbw7ARG-substrate interactions might be bolstered by allosteric
regulators, similar to a described inhibitor of the yeast Cdc4 pro-
tein (Orlicky et al., 2010).
Second, the downstream oncoproteins activated by Fbw7
mutations might be therapeutically targeted, rather than Fbw7
itself (Figure 3B). Studies with a pharmacologic Myc inhibitor in
mouse T-ALL suggest that this may be a viable strategy in
some cases (King et al., 2013). A variation of this approach has
been suggested for neuroblastoma, in which stable binding to
AURKA prevents N-Myc degradation by Fbw7. Small molecules
Figure 3. Potential Therapeutic Opportunities Targeting Fbw7
Pathway Mutations in Cancer
(A) Tumors with heterozygous Fbw7ARG mutations could be treated with a
small-molecule agonist (shown in purple) that restores the binding affinity
between the mutated Fbw7ARG b propeller and a phosphorylated substrate,
leading to oncoprotein ubiquitylation and proteasomal destruction.
(B) In cases where deregulation of particular Fbw7 substrates is necessary for
tumor cell survival, inhibiting the functions of the relevant substrates and/or
pathways, rather than targeting Fbw7 itself, may lead to antitumor activities.
This approach would be applicable to tumors containing any type of Fbw7
mutation.
(C) Synthetic lethality between decreased Fbw7 function and secondary
pathways (‘‘Pathway X’’) could lead to selective killing of tumor cells while
sparing other cells that have normal Fbw7 function. Similar to (B), synthetic
lethality could be applied to tumors containing any type of Fbw7 mutation.
(D) Because leukemia-initiating cells are exquisitely sensitive to Myc abun-
dance (Reavie et al., 2013; Takeishi et al., 2013), Fbw7 inhibition by small
molecules (or other approaches) may sufficiently increase Myc abundance to
cause LIC exhaustion and inhibit disease progression.
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Reviewthat dissociate N-Myc and AURKA allow the liberated N-Myc
to be targeted for degradation by Fbw7, leading to antitumor
effects (Brockmann et al., 2013).
Third, synthetic-lethal strategies can be utilized to identify and
pharmacologically target pathways that specifically inhibit can-
cers with Fbw7 pathway mutations while sparing normal cells
with intact Fbw7 function (Figure 3C). This approach could be
used against tumors with Fbw7 missense, nonsense, or null mu-
tations or in CPD mutant tumors such as Burkitt’s lymphoma.
Finally, studies in mice show that Fbw7 inhibition eliminates
CML by increasing Myc abundance, thereby leading to LIC
exhaustion (Reavie et al., 2013; Takeishi et al., 2013). This
work raised the idea that Myc toxicity in cancer stem cells might
provide the basis for using Fbw7 inhibition to eradicate LICs
(Figure 3D). However, inhibiting a potent tumor suppressor asa therapeutic strategy comes with obvious caveats, such as pro-
moting cancers in other sites.
Conclusions
Our understanding of the Fbw7 pathway’s role in tumorigenesis
has increased enormously over the past 5 years; new substrates
have deepened our understanding of the diverse oncogenic
pathways that Fbw7 regulates, and mouse models are providing
insights into how Fbw7 mutations lead to cancer. The conse-
quences of multiple oncoprotein deregulation by Fbw7 muta-
tions are still incompletely understood, but some general themes
are emerging. First, many Fbw7 substrates are broadly acting
TFs that regulate processes fundamental to carcinogenesis,
such as differentiation and proliferation. Therefore, Fbw7 mutant
tumors exhibit alterations in many of these pathways. Second,
Fbw7 has particularly important roles in normal and neoplastic
stem cells, and this probably impacts both tumor development
and therapeutic strategies. Third, genome instability is one
mechanism that may drive tumor progression, and several
Fbw7 substrates cause genomic instability when their activity
is abnormally high. Fourth, the biologic selection for Fbw7ARG
mutations most likely reflects their unique functions and may
provide important therapeutic opportunities. Finally, although
identifying critical Fbw7 substrates is important for understand-
ing tumorigenesis and discovering therapeutic targets, it should
be stressed that Fbw7mutations deregulate an entire network of
oncoproteins, and tumorigenesis almost certainly results from
their combined biologic output. The widely altered homeostasis
caused by Fbw7mutationsmay soon enable the development of
novel therapies targeting the Fbw7 pathway in cancer.
ACKNOWLEDGMENTS
The authors apologize to their many colleagues whose work could not be cited
due to space constraints. This work was supported by NIH grants CA084069
and CA102742 (B.E.C.) and by the National Science Foundation Graduate
Research Fellowship Program under grant numbers DGE-0718124 and
DGE-1256082 (R.J.D.).
REFERENCES
Akhoondi, S., Sun, D., von der Lehr, N., Apostolidou, S., Klotz, K., Maljukova,
A., Cepeda, D., Fiegl, H., Dafou, D., Marth, C., et al. (2007). FBXW7/hCDC4 is a
general tumor suppressor in human cancer. Cancer Res. 67, 9006–9012.
Akhoondi, S., Lindstro¨m, L., Widschwendter, M., Corcoran, M., Bergh, J.,
Spruck, C., Grande´r, D., and Sangfelt, O. (2010). Inactivation of FBXW7/
hCDC4-b expression by promoter hypermethylation is associated with favor-
able prognosis in primary breast cancer. Breast Cancer Res. 12, R105.
Babaei-Jadidi, R., Li, N., Saadeddin, A., Spencer-Dene, B., Jandke, A., Mu-
hammad, B., Ibrahim, E.E., Muraleedharan, R., Abuzinadah, M., Davis, H.,
et al. (2011). FBXW7 influences murine intestinal homeostasis and cancer,
targeting Notch, Jun, and DEK for degradation. J. Exp. Med. 208, 295–312.
Bahram, F., von der Lehr, N., Cetinkaya, C., and Larsson, L.G. (2000). c-Myc
hot spot mutations in lymphomas result in inefficient ubiquitination and
decreased proteasome-mediated turnover. Blood 95, 2104–2110.
Balamurugan, K., Sharan, S., Klarmann, K.D., Zhang, Y., Coppola, V., Sum-
mers, G.H., Roger, T., Morrison, D.K., Keller, J.R., and Sterneck, E. (2013).
FBXW7a attenuates inflammatory signalling by downregulating C/EBPd and
its target gene Tlr4. Nat. Commun. 4, 1662.
Bengoechea-Alonso, M.T., and Ericsson, J. (2010a). Tumor suppressor Fbxw7
regulates TGFb signaling by targeting TGIF1 for degradation. Oncogene 29,
5322–5328.Cancer Cell 26, October 13, 2014 ª2014 Elsevier Inc. 461
Cancer Cell
ReviewBengoechea-Alonso, M.T., and Ericsson, J. (2010b). The ubiquitin ligase
Fbxw7 controls adipocyte differentiation by targeting C/EBPalpha for degra-
dation. Proc. Natl. Acad. Sci. USA 107, 11817–11822.
Bhatia, K., Huppi, K., Spangler, G., Siwarski, D., Iyer, R., andMagrath, I. (1993).
Point mutations in the c-Myc transactivation domain are common in Burkitt’s
lymphoma and mouse plasmacytomas. Nat. Genet. 5, 56–61.
Bialkowska, A.B., Liu, Y., Nandan, M.O., and Yang, V.W. (2014). A colon can-
cer-derived mutant of Kru¨ppel-like factor 5 (KLF5) is resistant to degradation
by glycogen synthase kinase 3b (GSK3b) and the E3 ubiquitin ligase F-box
andWD repeat domain-containing 7a (FBW7a). J. Biol. Chem.289, 5997–6005.
Bonetti, P., Davoli, T., Sironi, C., Amati, B., Pelicci, P.G., and Colombo, E.
(2008). Nucleophosmin and its AML-associated mutant regulate c-Myc turn-
over through Fbw7 gamma. J. Cell Biol. 182, 19–26.
Brockmann, M., Poon, E., Berry, T., Carstensen, A., Deubzer, H.E., Rycak, L.,
Jamin, Y., Thway, K., Robinson, S.P., Roels, F., et al. (2013). Small molecule
inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood
neuroblastoma. Cancer Cell 24, 75–89.
Busino, L., Millman, S.E., Scotto, L., Kyratsous, C.A., Basrur, V., O’Connor, O.,
Hoffmann, A., Elenitoba-Johnson, K.S., and Pagano, M. (2012). Fbxw7a- and
GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple
myeloma. Nat. Cell Biol. 14, 375–385.
Cancer Genome Atlas Network (2012). Comprehensive molecular character-
ization of human colon and rectal cancer. Nature 487, 330–337.
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Ja-
cobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer
genomics portal: an open platform for exploring multidimensional cancer ge-
nomics data. Cancer Discov. 2, 401–404.
Cheng, Y., Chen, G., Martinka, M., Ho, V., and Li, G. (2013). Prognostic sig-
nificance of Fbw7 in human melanoma and its role in cell migration.
J. Invest. Dermatol. 133, 1794–1802.
Clurman, B.E., Sheaff, R.J., Thress, K., Groudine, M., andRoberts, J.M. (1996).
Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2
binding and cyclin phosphorylation. Genes Dev. 10, 1979–1990.
Crusio, K.M., King, B., Reavie, L.B., and Aifantis, I. (2010). The ubiquitous
nature of cancer: the role of the SCF(Fbw7) complex in development and
transformation. Oncogene 29, 4865–4873.
Davis, H., and Tomlinson, I. (2012). CDC4/FBXW7 and the ‘just enough’ model
of tumourigenesis. J. Pathol. 227, 131–135.
Davis, M.A., Larimore, E.A., Fissel, B.M., Swanger, J., Taatjes, D.J., and Clur-
man, B.E. (2013). The SCF-Fbw7 ubiquitin ligase degrades MED13 and
MED13L and regulates CDK8 module association with Mediator. Genes
Dev. 27, 151–156.
Davis, H., Lewis, A., Behrens, A., and Tomlinson, I. (2014). Investigation of the
atypical FBXW7 mutation spectrum in human tumours by conditional expres-
sion of a heterozygous propellor tip missense allele in the mouse intestines.
Gut 63, 792–799.
Deshaies, R.J., and Joazeiro, C.A. (2009). RING domain E3 ubiquitin ligases.
Annu. Rev. Biochem. 78, 399–434.
Ekholm-Reed, S., Me´ndez, J., Tedesco, D., Zetterberg, A., Stillman, B., and
Reed, S.I. (2004). Deregulation of cyclin E in human cells interferes with prere-
plication complex assembly. J. Cell Biol. 165, 789–800.
Ekholm-Reed, S., Goldberg, M.S., Schlossmacher, M.G., and Reed, S.I.
(2013). Parkin-dependent degradation of the F-box protein Fbw7b promotes
neuronal survival in response to oxidative stress by stabilizing Mcl-1. Mol.
Cell. Biol. 33, 3627–3643.
Finley, D. (2009). Recognition and processing of ubiquitin-protein conjugates
by the proteasome. Annu. Rev. Biochem. 78, 477–513.
Fryer, C.J., White, J.B., and Jones, K.A. (2004). Mastermind recruits
CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with
turnover. Mol. Cell 16, 509–520.
Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun,
Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis
of complex cancer genomics and clinical profiles using the cBioPortal. Sci.
Signal. 6, pl1.462 Cancer Cell 26, October 13, 2014 ª2014 Elsevier Inc.Gregory, M.A., Qi, Y., and Hann, S.R. (2003). Phosphorylation by glycogen
synthase kinase-3 controls c-myc proteolysis and subnuclear localization.
J. Biol. Chem. 278, 51606–51612.
Grim, J.E., Gustafson, M.P., Hirata, R.K., Hagar, A.C., Swanger, J., Welcker,
M., Hwang, H.C., Ericsson, J., Russell, D.W., and Clurman, B.E. (2008).
Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiqui-
tin ligase. J. Cell Biol. 181, 913–920.
Grim, J.E., Knoblaugh, S.E., Guthrie, K.A., Hagar, A., Swanger, J., Hespelt, J.,
Delrow, J.J., Small, T., Grady, W.M., Nakayama, K.I., and Clurman, B.E.
(2012). Fbw7 and p53 cooperatively suppress advanced and chromosomally
unstable intestinal cancer. Mol. Cell. Biol. 32, 2160–2167.
Gu, Z., Inomata, K., Mitsui, H., and Horii, A. (2008a). Promoter hypermethy-
lation is not the major mechanism for inactivation of the FBXW7 beta-form in
human gliomas. Genes Genet. Syst. 83, 347–352.
Gu, Z., Mitsui, H., Inomata, K., Honda, M., Endo, C., Sakurada, A., Sato, M.,
Okada, Y., Kondo, T., and Horii, A. (2008b). The methylation status of
FBXW7 beta-form correlates with histological subtype in human thymoma.
Biochem. Biophys. Res. Commun. 377, 685–688.
Gupta-Rossi, N., Le Bail, O., Gonen, H., Brou, C., Logeat, F., Six, E., Ciechan-
over, A., and Israe¨l, A. (2001). Functional interaction between SEL-10, an F-box
protein, and the nuclear form of activated Notch1 receptor. J. Biol. Chem. 276,
34371–34378.
Hao, B., Oehlmann, S., Sowa, M.E., Harper, J.W., and Pavletich, N.P. (2007).
Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated sub-
strate recognition by SCF ubiquitin ligases. Mol. Cell 26, 131–143.
Hershko, A., and Ciechanover, A. (1998). The ubiquitin system. Annu. Rev. Bio-
chem. 67, 425–479.
Hoeck, J.D., Jandke, A., Blake, S.M., Nye, E., Spencer-Dene, B., Brandner, S.,
and Behrens, A. (2010). Fbw7 controls neural stem cell differentiation and pro-
genitor apoptosis via Notch and c-Jun. Nat. Neurosci. 13, 1365–1372.
Inuzuka, H., Shaik, S., Onoyama, I., Gao, D., Tseng, A., Maser, R.S., Zhai, B.,
Wan, L., Gutierrez, A., Lau, A.W., et al. (2011). SCF(FBW7) regulates cellular
apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471,
104–109.
Kanatsu-Shinohara, M., Onoyama, I., Nakayama, K.I., and Shinohara, T.
(2014). Skp1-Cullin-F-box (SCF)-type ubiquitin ligase FBXW7 negatively regu-
lates spermatogonial stem cell self-renewal. Proc. Natl. Acad. Sci. USA 111,
8826–8831.
Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robert-
son, A.G., Pashtan, I., Shen, R., Benz, C.C., et al.; Cancer Genome Atlas
Research Network (2013a). Integrated genomic characterization of endome-
trial carcinoma. Nature 497, 67–73.
Kandoth, C., McLellan, M.D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang,
Q., McMichael, J.F., Wyczalkowski, M.A., et al. (2013b). Mutational landscape
and significance across 12 major cancer types. Nature 502, 333–339.
Keck, J.M., Summers, M.K., Tedesco, D., Ekholm-Reed, S., Chuang, L.C.,
Jackson, P.K., and Reed, S.I. (2007). Cyclin E overexpression impairs progres-
sion through mitosis by inhibiting APC(Cdh1). J. Cell Biol. 178, 371–385.
Kimura, T., Gotoh, M., Nakamura, Y., and Arakawa, H. (2003). hCDC4b, a
regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci. 94,
431–436.
King, B., Trimarchi, T., Reavie, L., Xu, L., Mullenders, J., Ntziachristos, P., Ara-
nda-Orgilles, B., Perez-Garcia, A., Shi, J., Vakoc, C., et al. (2013). The ubiquitin
ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC
stability. Cell 153, 1552–1566.
Koepp, D.M., Schaefer, L.K., Ye, X., Keyomarsi, K., Chu, C., Harper, J.W., and
Elledge, S.J. (2001). Phosphorylation-dependent ubiquitination of cyclin E by
the SCFFbw7 ubiquitin ligase. Science 294, 173–177.
Kwon, Y.W., Kim, I.J., Wu, D., Lu, J., Stock, W.A., Jr., Liu, Y., Huang, Y., Kang,
H.C., DelRosario, R., Jen, K.Y., et al. (2012). Pten regulates Aurora-A and co-
operates with Fbxw7 in modulating radiation-induced tumor development.
Mol. Cancer Res. 10, 834–844.
Lee, E.K., and Diehl, J.A. (2014). SCFs in the new millennium. Oncogene 33,
2011–2018.
Cancer Cell
ReviewLiu, N., Li, H., Li, S., Shen, M., Xiao, N., Chen, Y., Wang, Y., Wang, W., Wang,
R., Wang, Q., et al. (2010). The Fbw7/human CDC4 tumor suppressor targets
proproliferative factor KLF5 for ubiquitination and degradation through multi-
ple phosphodegron motifs. J. Biol. Chem. 285, 18858–18867.
Loeb, K.R., Kostner, H., Firpo, E., Norwood, T., D Tsuchiya, K., Clurman, B.E.,
and Roberts, J.M. (2005). A mouse model for cyclin E-dependent genetic
instability and tumorigenesis. Cancer Cell 8, 35–47.
Malyukova, A., Dohda, T., von der Lehr, N., Akhoondi, S., Corcoran, M., Hey-
man, M., Spruck, C., Grande´r, D., Lendahl, U., and Sangfelt, O. (2007). The tu-
mor suppressor gene hCDC4 is frequently mutated in human T-cell acute
lymphoblastic leukemia with functional consequences for Notch signaling.
Cancer Res. 67, 5611–5616.
Maser, R.S., Choudhury, B., Campbell, P.J., Feng, B., Wong, K.K., Protopo-
pov, A., O’Neil, J., Gutierrez, A., Ivanova, E., Perna, I., et al. (2007). Chromoso-
mally unstable mouse tumours have genomic alterations similar to diverse
human cancers. Nature 447, 966–971.
Matsumoto, A., Tateishi, Y., Onoyama, I., Okita, Y., Nakayama, K., and Na-
kayama, K.I. (2011). Fbxw7b resides in the endoplasmic reticulum membrane
and protects cells from oxidative stress. Cancer Sci. 102, 749–755.
Matsuoka, S., Oike, Y., Onoyama, I., Iwama, A., Arai, F., Takubo, K., Mashimo,
Y., Oguro, H., Nitta, E., Ito, K., et al. (2008). Fbxw7 acts as a critical fail-safe
against premature loss of hematopoietic stem cells and development of T-
ALL. Genes Dev. 22, 986–991.
Min, S.H., Lau, A.W., Lee, T.H., Inuzuka, H., Wei, S., Huang, P., Shaik, S., Lee,
D.Y., Finn, G., Balastik, M., et al. (2012). Negative regulation of the stability and
tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol. Cell 46,
771–783.
Minella, A.C., Swanger, J., Bryant, E., Welcker, M., Hwang, H., and Clurman,
B.E. (2002). p53 and p21 form an inducible barrier that protects cells against
cyclin E-cdk2 deregulation. Curr. Biol. 12, 1817–1827.
Minella, A.C., Grim, J.E., Welcker, M., and Clurman, B.E. (2007). p53 and
SCFFbw7 cooperatively restrain cyclin E-associated genome instability.
Oncogene 26, 6948–6953.
Minella, A.C., Loeb, K.R., Knecht, A., Welcker, M., Varnum-Finney, B.J., Bern-
stein, I.D., Roberts, J.M., and Clurman, B.E. (2008). Cyclin E phosphorylation
regulates cell proliferation in hematopoietic and epithelial lineages in vivo.
Genes Dev. 22, 1677–1689.
Nakayama, K.I., and Nakayama, K. (2006). Ubiquitin ligases: cell-cycle control
and cancer. Nat. Rev. Cancer 6, 369–381.
Nash, P., Tang, X., Orlicky, S., Chen, Q., Gertler, F.B., Mendenhall, M.D.,
Sicheri, F., Pawson, T., and Tyers, M. (2001). Multisite phosphorylation of a
CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414,
514–521.
Nateri, A.S., Riera-Sans, L., Da Costa, C., and Behrens, A. (2004). The ubiquitin
ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 303, 1374–
1378.
O’Neil, J., Grim, J., Strack, P., Rao, S., Tibbitts, D., Winter, C., Hardwick, J.,
Welcker, M., Meijerink, J.P., Pieters, R., et al. (2007). FBW7 mutations
in leukemic cells mediate NOTCH pathway activation and resistance to
gamma-secretase inhibitors. J. Exp. Med. 204, 1813–1824.
Oberg, C., Li, J., Pauley, A., Wolf, E., Gurney, M., and Lendahl, U. (2001). The
Notch intracellular domain is ubiquitinated and negatively regulated by the
mammalian Sel-10 homolog. J. Biol. Chem. 276, 35847–35853.
Olive, V., Sabio, E., Bennett, M.J., De Jong, C.S., Biton, A., McGann, J.C.,
Greaney, S.K., Sodir, N.M., Zhou, A.Y., Balakrishnan, A., et al. (2013). A
component of the mir-17-92 polycistronic oncomir promotes oncogene-
dependent apoptosis. Elife 2, e00822.
Olson, B.L., Hock, M.B., Ekholm-Reed, S., Wohlschlegel, J.A., Dev, K.K.,
Kralli, A., and Reed, S.I. (2008). SCFCdc4 acts antagonistically to the PGC-
1alpha transcriptional coactivator by targeting it for ubiquitin-mediated prote-
olysis. Genes Dev. 22, 252–264.
Onoyama, I., Tsunematsu, R., Matsumoto, A., Kimura, T., de Albora´n, I.M.,
Nakayama, K., and Nakayama, K.I. (2007). Conditional inactivation of Fbxw7
impairs cell-cycle exit during T cell differentiation and results in lymphomato-
genesis. J. Exp. Med. 204, 2875–2888.Onoyama, I., Suzuki, A., Matsumoto, A., Tomita, K., Katagiri, H., Oike, Y.,
Nakayama, K., and Nakayama, K.I. (2011). Fbxw7 regulates lipid metabolism
and cell fate decisions in the mouse liver. J. Clin. Invest. 121, 342–354.
Orlicky, S., Tang, X., Willems, A., Tyers, M., and Sicheri, F. (2003). Structural
basis for phosphodependent substrate selection and orientation by the
SCFCdc4 ubiquitin ligase. Cell 112, 243–256.
Orlicky, S., Tang, X., Neduva, V., Elowe, N., Brown, E.D., Sicheri, F., and Tyers,
M. (2010). An allosteric inhibitor of substrate recognition by the SCF(Cdc4)
ubiquitin ligase. Nat. Biotechnol. 28, 733–737.
Rajagopalan, H., Jallepalli, P.V., Rago, C., Velculescu, V.E., Kinzler, K.W.,
Vogelstein, B., and Lengauer, C. (2004). Inactivation of hCDC4 can cause
chromosomal instability. Nature 428, 77–81.
Reavie, L., Della Gatta, G., Crusio, K., Aranda-Orgilles, B., Buckley, S.M.,
Thompson, B., Lee, E., Gao, J., Bredemeyer, A.L., Helmink, B.A., et al.
(2010). Regulation of hematopoietic stem cell differentiation by a single ubiq-
uitin ligase-substrate complex. Nat. Immunol. 11, 207–215.
Reavie, L., Buckley, S.M., Loizou, E., Takeishi, S., Aranda-Orgilles, B., Ndiaye-
Lobry, D., Abdel-Wahab, O., Ibrahim, S., Nakayama, K.I., and Aifantis, I.
(2013). Regulation of c-Myc ubiquitination controls chronic myelogenous
leukemia initiation and progression. Cancer Cell 23, 362–375.
Sancho, R., Jandke, A., Davis, H., Diefenbacher, M.E., Tomlinson, I., and
Behrens, A. (2010). F-box andWD repeat domain-containing 7 regulates intes-
tinal cell lineage commitment and is a haploinsufficient tumor suppressor.
Gastroenterology 139, 929–941.
Sancho, R., Blake, S.M., Tendeng, C., Clurman, B.E., Lewis, J., and Behrens,
A. (2013). Fbw7 repression by hes5 creates a feedback loop that modulates
Notch-mediated intestinal and neural stem cell fate decisions. PLoS Biol. 11,
e1001586.
Sancho, R.,Gruber, R., Gu,G., andBehrens,A. (2014). Lossof Fbw7 reprograms
adult pancreatic ductal cells into a, d, and b cells. Cell Stem Cell 15, 139–153.
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., and Nevins, J.R. (2000).
Multiple Ras-dependent phosphorylation pathways regulate Myc protein
stability. Genes Dev. 14, 2501–2514.
Siu, K.T., Xu, Y., Swartz, K.L., Bhattacharyya, M., Gurbuxani, S., Hua, Y., and
Minella, A.C. (2014). Chromosome instability underlies hematopoietic stem
cell dysfunction and lymphoid neoplasia associated with impaired Fbw7-
mediated cyclin E regulation. Mol. Cell. Biol. 34, 3244–3258.
Skaar, J.R., Pagan, J.K., and Pagano, M. (2013). Mechanisms and function of
substrate recruitment by F-box proteins. Nat. Rev. Mol. Cell Biol. 14, 369–381.
Spruck, C.H., Won, K.A., and Reed, S.I. (1999). Deregulated cyclin E induces
chromosome instability. Nature 401, 297–300.
Spruck, C.H., Strohmaier, H., Sangfelt, O., Mu¨ller, H.M., Hubalek, M., Mu¨ller-
Holzner, E., Marth, C., Widschwendter, M., and Reed, S.I. (2002). hCDC4 gene
mutations in endometrial cancer. Cancer Res. 62, 4535–4539.
Strohmaier, H., Spruck, C.H., Kaiser, P., Won, K.A., Sangfelt, O., and Reed,
S.I. (2001). Human F-box protein hCdc4 targets cyclin E for proteolysis and
is mutated in a breast cancer cell line. Nature 413, 316–322.
Takeishi, S., Matsumoto, A., Onoyama, I., Naka, K., Hirao, A., and Nakayama,
K.I. (2013). Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing
quiescence. Cancer Cell 23, 347–361.
Tan, X., Calderon-Villalobos, L.I., Sharon, M., Zheng, C., Robinson, C.V.,
Estelle, M., and Zheng, N. (2007). Mechanism of auxin perception by the
TIR1 ubiquitin ligase. Nature 446, 640–645.
Tang, X., Orlicky, S., Lin, Z., Willems, A., Neculai, D., Ceccarelli, D., Mercurio,
F., Shilton, B.H., Sicheri, F., and Tyers, M. (2007). Suprafacial orientation of
the SCFCdc4 dimer accommodates multiple geometries for substrate ubiqui-
tination. Cell 129, 1165–1176.
Tetzlaff, M.T., Yu, W., Li, M., Zhang, P., Finegold, M., Mahon, K., Harper, J.W.,
Schwartz, R.J., and Elledge, S.J. (2004). Defective cardiovascular develop-
ment and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-
box protein. Proc. Natl. Acad. Sci. USA 101, 3338–3345.
Thompson, B.J., Buonamici, S., Sulis, M.L., Palomero, T., Vilimas, T., Basso,
G., Ferrando, A., and Aifantis, I. (2007). The SCFFBW7 ubiquitin ligase complex
as a tumor suppressor in T cell leukemia. J. Exp. Med. 204, 1825–1835.Cancer Cell 26, October 13, 2014 ª2014 Elsevier Inc. 463
Cancer Cell
ReviewThompson, B.J., Jankovic, V., Gao, J., Buonamici, S., Vest, A., Lee, J.M., Za-
vadil, J., Nimer, S.D., and Aifantis, I. (2008). Control of hematopoietic stem
cell quiescence by the E3 ubiquitin ligase Fbw7. J. Exp. Med. 205, 1395–
1408.
Tsunematsu, R., Nakayama, K., Oike, Y., Nishiyama, M., Ishida, N., Hata-
keyama, S., Bessho, Y., Kageyama, R., Suda, T., and Nakayama, K.I. (2004).
Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular
development. J. Biol. Chem. 279, 9417–9423.
van Drogen, F., Sangfelt, O., Malyukova, A., Matskova, L., Yeh, E., Means,
A.R., and Reed, S.I. (2006). Ubiquitylation of cyclin E requires the sequential
function of SCF complexes containing distinct hCdc4 isoforms. Mol. Cell 23,
37–48.
Wang, Z., Inuzuka, H., Zhong, J., Wan, L., Fukushima, H., Sarkar, F.H., and
Wei, W. (2012). Tumor suppressor functions of FBW7 in cancer development
and progression. FEBS Lett. 586, 1409–1418.
Wang, L., Ye, X., Liu, Y., Wei, W., and Wang, Z. (2014). Aberrant regulation of
FBW7 in cancer. Oncotarget 5, 2000–2015.
Wei, W., Jin, J., Schlisio, S., Harper, J.W., and Kaelin, W.G., Jr. (2005). The
v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition
and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8, 25–33.
Welcker,M., and Clurman, B.E. (2007). Fbw7/hCDC4 dimerization regulates its
substrate interactions. Cell Div. 2, 7.
Welcker, M., and Clurman, B.E. (2008). FBW7 ubiquitin ligase: a tumour
suppressor at the crossroads of cell division, growth and differentiation. Nat.
Rev. Cancer 8, 83–93.
Welcker, M., Singer, J., Loeb, K.R., Grim, J., Bloecher, A., Gurien-West, M.,
Clurman, B.E., and Roberts, J.M. (2003). Multisite phosphorylation by Cdk2
and GSK3 controls cyclin E degradation. Mol. Cell 12, 381–392.
Welcker, M., Orian, A., Grim, J.E., Eisenman, R.N., and Clurman, B.E. (2004a).
A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size.
Curr. Biol. 14, 1852–1857.464 Cancer Cell 26, October 13, 2014 ª2014 Elsevier Inc.Welcker, M., Orian, A., Jin, J., Grim, J.E., Harper, J.W., Eisenman, R.N., and
Clurman, B.E. (2004b). The Fbw7 tumor suppressor regulates glycogen syn-
thase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc.
Natl. Acad. Sci. USA 101, 9085–9090.
Welcker, M., Larimore, E.A., Swanger, J., Bengoechea-Alonso, M.T., Grim,
J.E., Ericsson, J., Zheng, N., and Clurman, B.E. (2013). Fbw7 dimerization
determines the specificity and robustness of substrate degradation. Genes
Dev. 27, 2531–2536.
Weng, A.P., Ferrando, A.A., Lee, W., Morris, J.P., 4th, Silverman, L.B., San-
chez-Irizarry, C., Blacklow, S.C., Look, A.T., and Aster, J.C. (2004). Activating
mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science
306, 269–271.
Wertz, I.E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D.J.,
Helgason, E., Ernst, J.A., Eby, M., Liu, J., et al. (2011). Sensitivity to antitubulin
chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110–114.
Won, K.A., and Reed, S.I. (1996). Activation of cyclin E/CDK2 is coupled to
site-specific autophosphorylation and ubiquitin-dependent degradation of
cyclin E. EMBO J. 15, 4182–4193.
Wu, G., Lyapina, S., Das, I., Li, J., Gurney, M., Pauley, A., Chui, I., Deshaies,
R.J., and Kitajewski, J. (2001). SEL-10 is an inhibitor of notch signaling that tar-
gets notch for ubiquitin-mediated protein degradation. Mol. Cell. Biol. 21,
7403–7415.
Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki,
H., Ishida, N., Okumura, F., Nakayama, K., and Nakayama, K.I. (2004). Phos-
phorylation-dependent degradation of c-Myc is mediated by the F-box protein
Fbw7. EMBO J. 23, 2116–2125.
Zhang, W., and Koepp, D.M. (2006). Fbw7 isoform interaction contributes to
cyclin E proteolysis. Mol. Cancer Res. 4, 935–943.
Zhao, D., Zheng, H.Q., Zhou, Z., and Chen, C. (2010). The Fbw7 tumor sup-
pressor targets KLF5 for ubiquitin-mediated degradation and suppresses
breast cell proliferation. Cancer Res. 70, 4728–4738.
